x

Posted 02 November, 2023

BioCorRx Inc. appointed new CEO

CEO Change detected for ticker OTC:BICX in a 8-K filed on 02 November, 2023.


  Effective as of October 30, 2023, Lourdes Felix, the Company's Chief Executive Officer and Chief Financial Officer, assumed Mr. Granier's responsibilities during his paid administrative leave of absence.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of BioCorRx Inc.
Health Care/Life Sciences • Healthcare Provision
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. It offers treatment philosophy that combines medical intervention and a proprietary cognitive behavioral therapy program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatments. It also engages in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. The company was founded by Neil Terrence Muller and George O'Neill on January 28, 2008 and is headquartered in Anaheim, CA.
Market Cap
$7.91M
View Company Details
BioCorRx Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On October 30, 2023, the board of directors (the "Board") of BioCorRx Inc. (the "Company") approved Brady Granier's request for a paid administrative leave of absence from his position as the President of the Company for the period between October 30, 2023 and January 30, 2024. Mr. Granier will remain a member of the Board during this period.


Effective as of October 30, 2023, Lourdes Felix, the Company's Chief Executive Officer and Chief Financial Officer, assumed Mr. Granier's responsibilities during his paid administrative leave of absence. Ms. Felix's compensation remains unchanged.


2